Shield Therapeutics Management
Management criteria checks 3/4
Shield Therapeutics' CEO is Anders Lundstrom, appointed in Jul 2024, has a tenure of less than a year. directly owns 0.001% of the company’s shares, worth £350.36. The average tenure of the management team and the board of directors is 1.8 years and 4.2 years respectively.
Key information
Anders Lundstrom
Chief executive officer
US$53.5k
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.001% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.2yrs |
Recent management updates
Recent updates
Even With A 26% Surge, Cautious Investors Are Not Rewarding Shield Therapeutics plc's (LON:STX) Performance Completely
Feb 06
Shield Therapeutics plc (LON:STX) Stock's 28% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Oct 30Shield Therapeutics (LON:STX) Is Making Moderate Use Of Debt
Oct 12Shield Therapeutics plc's (LON:STX) Shares Leap 44% Yet They're Still Not Telling The Full Story
Aug 01Increases to Shield Therapeutics plc's (LON:STX) CEO Compensation Might Cool off for now
Jun 13Market Might Still Lack Some Conviction On Shield Therapeutics plc (LON:STX) Even After 35% Share Price Boost
May 22Here's Why We're Watching Shield Therapeutics' (LON:STX) Cash Burn Situation
Mar 02What Does The Future Hold For Shield Therapeutics plc (LON:STX)? These Analysts Have Been Cutting Their Estimates
May 06Shield Therapeutics (LON:STX) Shareholders Have Enjoyed An Impressive 111% Share Price Gain
Mar 15We're Interested To See How Shield Therapeutics (LON:STX) Uses Its Cash Hoard To Grow
Jan 27
CEO
Anders Lundstrom (62 yo)
less than a year
Tenure
US$53,542
Compensation
Mr. Anders Lundstrom has been its Chief Executive Officer since February 1, 2025 and was an Interim Chief Executive Officer of Shield Therapeutics plc since July 24, 2024 until February 1, 2025 and serves...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Independent Non-Executive Director | less than a year | US$53.54k | 0.0013% £ 350.4 | |
| Co-Founder & Non Executive Director | 17.1yrs | US$47.17k | 1.49% £ 407.8k | |
| Chief Financial Officer | 1.1yrs | no data | no data | |
| General Counsel & Company Secretary | 7.4yrs | no data | no data | |
| Group HR Director | no data | no data | no data | |
| Head of Pharmacovigilance & Medical Information | no data | no data | no data | |
| Chief Commercial Officer | 1.8yrs | no data | no data | |
| Senior Director of People & Culture | no data | no data | no data |
1.8yrs
Average Tenure
56.5yo
Average Age
Experienced Management: STX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Independent Non-Executive Director | 3.8yrs | US$53.54k | 0.0013% £ 350.4 | |
| Co-Founder & Non Executive Director | 4.7yrs | US$47.17k | 1.49% £ 407.8k | |
| Independent Non Executive Chairman | 6.6yrs | US$119.83k | 0.70% £ 192.5k | |
| Non-Executive Director | less than a year | no data | no data | |
| Independent Non-Executive Director | 9yrs | US$76.49k | 0.023% £ 6.2k | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Independent Non-Executive Director | 3.8yrs | US$47.17k | 0.035% £ 9.5k | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Notable Scientific Advisory Board | no data | no data | no data | |
| Notable Scientific Advisory Board | no data | no data | no data |
4.2yrs
Average Tenure
60yo
Average Age
Experienced Board: STX's board of directors are considered experienced (4.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/11 18:24 |
| End of Day Share Price | 2025/02/11 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Shield Therapeutics plc is covered by 11 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Howard Miller | Canaccord Genuity |
| Stuart Harris | Cavendish |
| Alexander Pye | Cavendish |